Explores the PAF-PAFR pathway and its role in liver disease severity in women with obesity, indicating possible therapeutic strategies.
The PAF-PAFR axis is upregulated in obesity-associated MASLD and is strongly linked to inflammatory and injury-related histological features, supporting PAFR as a potential therapeutic target. Conversely, plasma Lp-PLA2 does not appear to be a reliable noninvasive biomarker of MASLD severity in women with obesity.
No takes yet. Share an insight, caveat, or question.
Duran‐Bertran et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: